Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are observing children aged 7 to under 12 years with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol. This study aims to learn more about how this treatment works in preventing bleeding episodes during routine medical care. Participants have previously been treated with damoctocog alfa pegol or other factor VIII products, and the study focuses on their usual treatment without any changes or advice from the study team. Participants receive damoctocog alfa pegol as prescribed by their own doctors for regular continuous prophylaxis to prevent bleeding. The study collects data from routine medical care and does not require additional visits or tests. Historical medical records and interviews with patients and their guardians provide background information. Guardians also keep a health diary to record bleeding episodes and treatment, and complete questionnaires assessing the impact of hemophilia on daily life. Data collection occurs over two years or until participants leave the study or change treatment. Researchers track the number and type of bleeding episodes, treatment details including dosing and infusions, and overall health status. The main outcome measures include the number of treated bleeds documented in diaries. No extra procedures are needed beyond routine care, and the study monitors how damoctocog alfa pegol is used in real-world settings.